Redmile Group LLC increased its stake in Diplomat Pharmacy, Inc. (NYSE:DPLO) by 718.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,254,342 shares of the company’s stock after buying an additional 1,101,025 shares during the period. Diplomat Pharmacy accounts for approximately 1.3% of Redmile Group LLC’s holdings, making the stock its 29th largest position. Redmile Group LLC owned 1.88% of Diplomat Pharmacy worth $20,007,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in Diplomat Pharmacy by 73.1% in the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after buying an additional 3,056 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Diplomat Pharmacy by 13.8% in the first quarter. BNP Paribas Arbitrage SA now owns 8,876 shares of the company’s stock worth $142,000 after buying an additional 1,073 shares during the period. Janney Montgomery Scott LLC acquired a new position in shares of Diplomat Pharmacy during the first quarter worth $160,000. Weiss Multi Strategy Advisers LLC acquired a new position in shares of Diplomat Pharmacy during the first quarter worth $160,000. Finally, Mason Street Advisors LLC increased its position in shares of Diplomat Pharmacy by 8.4% in the first quarter. Mason Street Advisors LLC now owns 10,148 shares of the company’s stock worth $162,000 after buying an additional 783 shares during the period. Hedge funds and other institutional investors own 72.59% of the company’s stock.
Diplomat Pharmacy, Inc. (NYSE:DPLO) traded up 0.55% on Friday, reaching $14.51. 381,006 shares of the company were exchanged. The firm has a market capitalization of $974.36 million, a P/E ratio of 57.81 and a beta of 0.63. The firm has a 50-day moving average of $17.70 and a 200 day moving average of $15.30. Diplomat Pharmacy, Inc. has a 12-month low of $12.25 and a 12-month high of $38.94.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings data on Monday, May 8th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.08 billion. Diplomat Pharmacy had a net margin of 0.38% and a return on equity of 7.91%. The company’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 EPS. On average, equities analysts predict that Diplomat Pharmacy, Inc. will post $0.65 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/diplomat-pharmacy-inc-dplo-shares-bought-by-redmile-group-llc-updated-updated/1043592.html.
A number of equities research analysts have recently issued reports on the company. BidaskClub cut Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. Cowen and Company boosted their price target on Diplomat Pharmacy from $12.00 to $17.00 and gave the company a “market perform” rating in a research note on Tuesday, May 9th. Leerink Swann restated a “market perform” rating and set a $18.00 target price (up from $16.00) on shares of Diplomat Pharmacy in a research note on Wednesday, May 17th. Mizuho upped their target price on Diplomat Pharmacy from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 16th. Finally, Bank of America Corporation upped their price target on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the stock a “neutral” rating in a report on Thursday, May 25th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $21.07.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with our FREE daily email newsletter.